BioNeex Interviews
Interview with the CEO and Founder of A28 Therapeutics, Stanley Lewis
Jun 17, 2025
Cancer Therapies
The CEO of A28 Therapeutics, Stanley Lewis, is leading the development of a targeted cancer therapy platform built around lytic peptides that kill tumor cells while sparing healthy tissue. A28’s lead candidate, AT-101, selectively binds to LHRH receptors found on cancer cells, delivering a positively charged peptide that disrupts the tumor cell membrane and triggers immune activation.
Back 
Interview URL has been copied in the clipboard